autoimmune disease
-
Intas Pharmaceuticals in licensing agreement with mAbxience
The agreement accelerates Intas’ global mission to enable innovative and affordable treatment options for autoimmune diseases Intas Pharmaceuticals announced a…
Read More » -
Glenmark’s subsidiary Ichnos Sciences in licensing agreement with Almirall
Almirall is granted exclusive global rights to develop and commercialise ISB 880 for use in autoimmune diseases Ichnos Sciences, a…
Read More »